VBI Vaccines Inc.

NASDAQ:VBIV   11:25:05 AM EDT
1.55
+0.02 (+1.31%)
Products

VBI Vaccines To Present New Overall Survival Data From Phase 2A Study In Recurrent GBM

Published: 12/01/2021 21:58 GMT
VBI Vaccines Inc. (VBIV) - Vbi Vaccines to Present New Overall Survival Data From Phase 2a Study in Recurrent Gbm at the World Vaccine & Immunotherapy Congress 2021.
Vbi Vaccines Inc - Updated 12-month and 18-month Overall Survival Data Demonstrate Continued Improvements Compared to Historical Controls.
Vbi Vaccines - 1 Patient Remaining on Protocol Achieved Progression-free Survival Beyond 86 Weeks, Demonstrating 93% Tumor Reduction Relative to Baseline.